Heparin is the most complex chemical compound known in the world so far. It cannot be synthesized by artificial chemicals in a short time. At present, only heparin derived from the intestinal mucosa of pigs can be used for clinical treatment.

　　Heparin sodium manufacturer tells you the in vivo action characteristic of heparin:

　　1. Medicinal heparin is a biological preparation extracted from pig small intestine and bovine lung.

　　2. This product can accelerate antithrombin Ⅲ (AT Ⅲ) and activation of the coagulation factor, thrombin and make its inactivation, forming complexes produce anticoagulant effect in vivo and in vitro.

　　3. Fast and strong anticoagulant effect, used for thromboembolic diseases, DIC, cardiovascular surgery, etc.

　　4. Oral non-absorption, often intravenous administration.

　　5. Excessive dose may cause spontaneous bleeding, and long-term use may cause osteoporosis. Liver and kidney dysfunction, peptic ulcer, severe hypertension, pregnant women, with bleeding constitution should be used with caution.

　　Because heparin sodium has the physical and chemical properties of strong negative charge, it can interfere many links of the hemagglutination process, and it has the anticoagulant effect in vivo and in vitro. Its mechanism is complex, mainly through and antithrombin Ⅲ (AT - Ⅲ), and enhance the latter to activate Ⅱ, Ⅸ, Ⅹ, Ⅺ and Ⅻ inhibition of clotting factors.

　　It can prevent platelet aggregation and damage, and hinder the formation of thrombolytic activase. Preventing prothrombin from becoming prothrombin; Inhibit thrombin, thereby preventing fibrinogen from becoming fibrin, achieving the effect of anticoagulation.

　　The legend of the anticoagulant -- Heparin sodium:

　　Heparin sodium, as an anticoagulant, has an effect on many links of the coagulation process, and can prolong the coagulation time and prothrombin time. This product whether in vivo or in vitro, has a rapid anticoagulant effect, mainly on the formation of fibrin, can also reduce platelet aggregation.

　　It can be used for the prevention and treatment of thromboembolic diseases, such as myocardial infarction, pulmonary embolism, cerebral vascular embolism, peripheral venous thrombosis, etc., to prevent the formation and expansion of thrombosis, and can also be used for the early stage of DIC, and other in vivo and in vitro anticoagulation. Early application can prevent the depletion of fibrinogen and coagulation factor, and can also replace citrate in blood transfusion or extracorporeal anticoagulant in extracorporeal circulation.

　　Cardiovascular and cerebrovascular diseases are the number one killer of human diseases. With the improvement of people's living standards brought about by excess nutrition, the deterioration of the global environment, the accelerated pace of life, the aggravation of the aging of the population, resulting in the global incidence and mortality of cardiovascular and cerebrovascular diseases are increasing year by year, the emergence of heparin has created a miracle of life for many patients with cardiovascular and cerebrovascular diseases.

　　At present, heparin is the most effective anticoagulant drug with the largest clinical dosage in the world. It is mainly used in the treatment of cardiovascular and cerebrovascular diseases and hemodialysis, among which, heparin is the only effective specific drug in the treatment of hemodialysis. Clinical application and research show that heparin has a variety of other biological activities and clinical USES in addition to anticoagulant effect, including the effect of lowering blood lipid, anti-proliferation of mesofilm smooth muscle cells (SMC), promoting fibrinolysis and so on. In addition, LMWH is a large class of antithrombolytic drugs further processed from heparin API as raw materials, which has a wider range of clinical medical applications and has become the preferred drug for the treatment of acute venous thrombosis and acute coronary syndrome (angina, myocardial infarction) and other diseases.

　　In recent years, the international market has a very strong demand for heparin API, the dosage of heparin preparations has been rising steadily, and the market of low molecular weight heparin has expanded rapidly and maintained a high growth trend. The global heparin drug market is expected to reach $9.703 billion by 2014, with an estimated CAGR of 13.06%.

　　Heparin is the most complex chemical compound known in the world so far. It cannot be synthesized by artificial chemicals in a short time. At present, only heparin derived from the intestinal mucosa of pigs can be used for clinical treatment. The raw material of heparin API is crude heparin, which can only be extracted from the small intestine mucosa of healthy pigs. Due to the large amount of impurity protein, impurity nucleic acid, microorganism and other impurities, the heparin with complete natural structure group should be obtained through physical and chemical extraction and separation process, so as to make heparin API.

　　Heparin sodium API is the only active ingredient of standard heparin preparation and the starting point of production of low molecular weight heparin raw materials. Currently, heparin preparation is only used in clinic according to the way of injection administration, which makes heparin API need to have high purity to ensure the drug safety of the preparation.

　　For more information about heparin sodium, welcome to consult the heparin sodium manufacturer Kowloon Pharmaceutical.